# Metronomic Therapy in Metastatic Breast Cancer.

> **NCT01131195** · PHASE3 · COMPLETED · sponsor: **Swiss Cancer Institute** · enrollment: 139 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab, Paclitaxel
- **BIOLOGICAL:** Bevacizumab, Cyclophosphamide, Capecitabine

## Key facts

- **NCT ID:** NCT01131195
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07-19
- **Primary completion:** 2012-12-14
- **Final completion:** 2018-02-28
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2019-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01131195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01131195, "Metronomic Therapy in Metastatic Breast Cancer.". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT01131195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*